The choice between tirzepatide and semaglutide comes up in nearly every GLP-1 consultation these days. Both medications work by activating the GLP-1 pathway, both are delivered by injection, and both produce meaningful weight loss. But they're not identical, and the differences matter depending on your health history, goals, and what you're willing to manage in terms of side effects.

This comparison covers the clinical evidence for both medications, how their mechanisms differ, what the real-world side effect profiles look like, and how to think through the decision with your physician.

Semaglutide is a GLP-1 receptor agonist, meaning it specifically activates the receptor in your body that responds to the GLP-1 hormone. This slows gastric emptying, reduces appetite signals in the brain, and improves insulin secretion in response to food. It's the active ingredient in Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management).

Tirzepatide does everything semaglutide does, and then some. It's a dual GIP/GLP-1 receptor agonist, meaning it activates two distinct receptors simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that plays a role in fat storage, insulin secretion, and energy metabolism. The combination of both receptor activations appears to produce greater weight loss than GLP-1 activation alone. Tirzepatide is the active ingredient in Mounjaro (diabetes) and Zepbound (obesity).

The practical implication: tirzepatide hits two targets, and the clinical data reflects that.

The STEP trial program for semaglutide and the SURMOUNT trial program for tirzepatide are the most rigorous sources of evidence here. These are large, randomized, placebo-controlled studies, which sets a relatively high bar for confidence.

In the STEP 1 trial, semaglutide 2.4mg produced an average weight loss of about 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. That's a clinically meaningful result. About one-third of participants lost 20% or more of their body weight.

In the SURMOUNT-1 trial, tirzepatide produced average weight loss of 15%, 19.5%, and 20.9% at the 5mg, 10mg, and 15mg doses respectively over 72 weeks. At the highest dose, more than half of participants lost at least 20% of body weight.

A 2023 head-to-head analysis published in JAMA Internal Medicine reviewed outcomes data across both trial programs and found tirzepatide consistently produced greater absolute weight loss, with the advantage most pronounced at higher doses.

For weight loss, tirzepatide appears to have a meaningful edge at equivalent doses. The gap isn't dramatic at lower tirzepatide doses versus semaglutide, but at tirzepatide's highest dose, the difference is clinically significant for patients whose primary goal is maximum weight reduction.

Both medications produce similar categories of side effects, primarily gastrointestinal in nature. Nausea, diarrhea, constipation, and vomiting are the most commonly reported.

In STEP 1, about 44% of semaglutide patients reported nausea versus 16% on placebo. In SURMOUNT-1, nausea rates with tirzepatide ranged from about 22% to 31% depending on dose, with higher rates at the 15mg level.

Both sets of numbers suggest tirzepatide may produce somewhat less nausea than semaglutide at doses producing equivalent weight loss, though direct comparison studies are ongoing and individual responses vary considerably.

One side effect worth noting: both medications can cause injection site reactions, though these are generally mild. Both also carry a class warning regarding thyroid C-cell tumors based on rodent studies. Your physician will discuss this warning and what it means for your individual situation as part of your consultation.

Gallbladder problems are a real consideration with both medications. Rapid weight loss of any kind increases the risk of gallstones, and GLP-1 medications can affect gallbladder motility. Patients with a history of gallbladder disease should discuss this specifically with their physician.

This is where the practical reality of the US healthcare landscape matters.

Brand-name tirzepatide and semaglutide are both expensive without insurance coverage, often running $900 to over $1,200 per month at retail. Insurance coverage varies significantly by plan and diagnosis.

Compounded versions of both medications offer a more accessible price point for many patients. Compounded semaglutide in particular has been widely available through telehealth platforms. The regulatory status of compounded tirzepatide has been more complex due to FDA shortage designations changing over time.

EllieMD's weight loss program uses compounded semaglutide with physician oversight, making the cost significantly more accessible than brand-name alternatives for most patients. Your consultation will include a full discussion of options, pricing, and what to expect.

There's no universal answer, and anyone who tells you otherwise isn't accounting for the variables that matter.

If maximum weight loss is the primary goal and you're otherwise a good candidate for either medication, the clinical evidence gives tirzepatide a modest advantage, particularly at higher doses. If access or cost is a limiting factor, semaglutide via compounding tends to be more straightforward to obtain.

If you've previously tried semaglutide and had significant side effects, tirzepatide may or may not be better tolerated; the mechanisms overlap enough that both GI side effects are possible. On the other hand, some patients who struggled on semaglutide have done considerably better on tirzepatide, possibly because the different receptor balance produces a different GI profile for them individually.

If you're managing type 2 diabetes alongside obesity, both medications have approval in the diabetes indication and your prescribing physician will consider your blood sugar control, other medications, and any comorbidities as part of the decision.

The right starting point is a conversation with a licensed physician who can review your full picture. EllieMD's consultation process is built around exactly that.

For a deeper look at how either medication fits into a broader weight loss approach, see our guide on GLP-1 microdosing and our weight loss program overview.

Individual results may vary. All prescriptions require approval by a licensed medical provider. Compounded medications are not FDA-approved. EllieMD facilitates access to independent healthcare providers and pharmacies and does not provide medical care or dispense medications.